This article examines post-market drug safety, highlighting surveillance mechanisms, regulatory responses, and case studies of approved drugs with hidden risks.
Akebia Therapeutics gets EMA panel support for Xoanacyl to treat high phosphate & iron deficiency in CKD. Read more here.
Mizuho says that while “any clinical hold is concerning,” the European Medicines Agency’s request to pause the three Elevidys studies will ...
The European Commission has referred Eisai and Biogen’s application to an appeals committee. Elsewhere, Opthea warned of ...
The Global Baby Products Market is projected to grow at a CAGR of 4.5% from 2026 to 2033, according to a new report published by Verified Market Reports®. The report reveals that the market was valued ...
Icelandic drug discovery and development company Arctic Therapeutics (ATx) today announced the publication of research in JAMA Neurology, which informs a possible therapeutic strategy to treat a rare ...
1d
Louisville Public Media on MSNEli Lilly's Alzheimer's drug not recommended by top European regulatorEli Lilly's Alzheimer's treatment is approved for use in the U.S. but the European Medicines Agency recommended against the ...
Accord Healthcare Limited (Accord) is pleased to announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for ...
A key result of a workshop series of European regulatory authorities and HTA agencies: Drug studies should be designed in such a way that they address both regulatory questions and the essential ...
M Co., Bioject Medical Technologies Inc., Valeritas Inc., Antares Pharma Inc., and Endo International PLC Lead the Competitive LandscapeDublin, April 01, 2025 (GLOBE NEWSWIRE) -- The "Needle Free ...
Novo Nordisk today presented the full results from the SOUL cardiovascular outcomes trial, demonstrating that Rybelsus® (oral ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results